Hyperfine (HYPR) Net Equity Issued and Repurchased (2025 - 2026)

Hyperfine (HYPR) posted Net Equity Issued and Repurchased of $824000.0 for Q1 2026, up 68.85% on a QoQ basis from $488000.0 in Q4 2025, and down 84.8% year-over-year from $5.4 million in Q1 2025.

Hyperfine (HYPR) Net Equity Issued and Repurchased (2025 - 2026) Analysis & Trends

Hyperfine's Net Equity Issued and Repurchased history runs 2 years deep, the most recent figure standing at $824000.0 for Q1 2026.

  • Quarterly Net Equity Issued and Repurchased fell 84.8% year-over-year to $824000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $4.2 million (changed N/A YoY) and the FY2025 annual result came in at $3.5 million, changed N/A from the prior year.
  • Net Equity Issued and Repurchased was $824000.0 for Q1 2026 at Hyperfine, up from $488000.0 in the prior quarter.
  • Across five years, Net Equity Issued and Repurchased topped out at $5.4 million in Q1 2025 and bottomed at $488000.0 in Q4 2025.
Generated on {Timestamp} © BusinessQuant.com
Generated on {Timestamp} Powered by BusinessQuant Logo

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Net Equity Issued and Repurchased (Qtr)
1 Abbott Laboratories 201.40 Bn 194.75 Bn 6.27 Bn -
2 Stryker 122.29 Bn 119.41 Bn 3.81 Bn -
3 Medtronic 105.01 Bn 96.40 Bn 6.41 Bn 97.00 Mn
4 Boston Scientific 64.81 Bn 63.59 Bn 3.61 Bn -
5 Edwards Lifesciences 55.28 Bn 51.60 Bn 1.29 Bn -
6 Dexcom 29.06 Bn 27.94 Bn 750.30 Mn 12.70 Mn
7 Koninklijke Philips 29.02 Bn 25.93 Bn 2.07 Bn -
8 GE HealthCare Technologies 28.27 Bn 26.20 Bn 1.98 Bn -
9 Smith & Nephew 25.80 Bn 25.22 Bn - -
10 Hyperfine 92.81 Mn 51.53 Mn 1.98 Mn 824,000.00

Historic Data

Download Data
DateValue
Mar 31, 2026 824,000.00
Mar 31, 2026 824,000.00
Dec 31, 2025 488,000.00
Dec 31, 2025 488,000.00
Sep 30, 2025 2.12 Mn
Sep 30, 2025 2.12 Mn
Jun 30, 2025 725,000.00
Jun 30, 2025 725,000.00
Mar 31, 2025 5.42 Mn
Mar 31, 2025 5.42 Mn